Fertility preservation in ovarian tumours

A considerable number of patients with a cancer diagnosis are of childbearing age and have not satisfied their desire for a family. Despite ovarian cancer (OC) usually occurring in older patients, 3%–14% are diagnosed at a fertile age with the overall 5-year survival rate being 91.2% in women ≤44 years of age when it is found at 1A–B stage. In this scenario, testing the safety and the efficacy of fertility sparing strategies in OC patients is very important overall in terms of quality of life. Unfortunately, the lack of randomised trials to validate conservative approaches does not guarantee the safety of fertility preservation strategies. However, evidence-based data from descriptive series suggest that in selected cases, the preservation of the uterus and at least one part of the ovary does not lead to a high risk of relapse. This conservative surgery helps to maintain organ function, giving patients of childbearing age the possibility to preserve their fertility. We hereby analysed the main evidence from the international literature on this topic in order to highlight the selected criteria for conservative management of OC patients, including healthy BRCA mutations carriers

Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials

Background: To analyze the efficacy and toxicity of bevacizumab on survival outcomes in recurrent ovarian cancer. Results: Bevacizumab was associated with significant improvement of PFS and OS compared with standard treatment with HRs of 0.53 (95% CI 0.44 - 0.63; p < 0.00001) and 0.87 (95% CI, 0.77 to 0.99; p = 0.03), respectively. Bevacizumab increased the incidence of G3/G4 hypertension (RR 19.01, 95% CI 7.77 - 46.55; p < 0.00001), proteinuria (RR 17.31, 95% CI 5.42 - 55.25; p < 0.00001), arterial thromboembolic events (ATE) (RR 4.99, 95% CI 1.29 - 19.27; p = 0.02) and bleeding (RR 3.14, 95% CI 1.35 - 7.32; p = 0.008). Materials and Methods: Three randomized phase III trials representing 1502 patients were identified. Pooled hazard ratio (HR), odd ratio (OR), risk ratio (RR) with 95% confidence interval (CI) were calculated using fixed or random effects model. Conclusions: Adding bevacizumab to standard chemotherapy improved ORR, PFS and OS, and it had a higher, but manageable, incidence of toxicities graded 3 to 4

A global fit to determine the pseudoscalar mixing angle and the gluonium content of the eta' meson

We update the values of the eta-eta' mixing angle and of the eta' gluonium content by fitting our measurement R_phi = BR(phi to eta' gamma)/ BR(phi to eta gamma) together with several vector meson radiative decays to pseudoscalars (V to P gamma), pseudoscalar mesons radiative decays to vectors (P to V gamma) and the eta' to gamma gamma, pi^0 to gamma gamma widths. From the fit we extract a gluonium fraction of Z^2_G = 0.12 +- 0.04, the pseudoscalar mixing angle psi_P = (40.4 +- 0.6) degree and the phi-omega mixing angle psi_V = (3.32 +- 0.09) degree. Z^2_G and psi_P are fairly consistent with those previously published. We also evaluate the impact on the eta' gluonium content determination of future experimental improvements of the eta' branching ratios and decay width.Comment: 13 pages, 7 figures to submit to JHE

Measurement of the pseudoscalar mixing angle and η′\eta^{\prime} gluonium content with KLOE detector

We have measured the ratio $R_{\phi}=BR(\phi \to \eta^{\prime} \gamma)/BR(\phi \to \eta \gamma)$ by looking for the radiative decays $\phi \to \eta^{\prime} \gamma$ and $\phi \to \eta \gamma$ in the final states $\pi^+\pi^-$ 7 $\gamma$'s and 7 $\gamma$'s respectively, in a sample of $\sim 1.3\cdot 10^{9}$ $\phi$ mesons produced at the Frascati $\phi$-factory. We obtain $R_{\phi}=(4.77\pm0.09_{stat}\pm0.19_{sys})\cdot 10^{-3}$ from which we derive $BR(\phi \to \eta^{\prime} \gamma)=(6.20\pm0.11_{stat}\pm0.25_{sys})\cdot 10^{-5}$. In the hypothesis of no gluonium content we extract the pseudoscalar mixing angle in the quark-flavor basis $\phi_P=(41.4\pm0.3_{stat}\pm0.7_{sys}\pm0.6_{th})^{\circ}$. Combining the value of $R_{\phi}$ with other constraints, we estimate the gluonium fractional content of $\eta^{\prime}$ meson as $Z^2 = 0.14\pm0.04$ and the mixing angle $\phi_P = (39.7\pm0.7)^{\circ}$.Comment: 13 pages, 8 figure

A new limit on the CP violating decay KS -> 3pi0 with the KLOE experiment

We have carried out a new direct search for the CP violating decay KS -> 3pi0 with 1.7 fb^-1 of e+e- collisions collected by the KLOE detector at the phi-factory DAFNE. We have searched for this decay in a sample of about 5.9 x 10^8 KS KL events tagging the KS by means of the KL interaction in the calorimeter and requiring six prompt photons. With respect to our previous search, the analysis has been improved by increasing of a factor four the tagged sample and by a more effective background rejection of fake KS tags and spurious clusters. We find no candidates in data and simulated background samples, while we expect 0.12 standard model events. Normalizing to the number of KS -> 2pi0 events in the same sample, we set the upper limit on BR(KS -> 3pi0 < 2.6 x 10^-8 at 90% C.L., five times lower than the previous limit. We also set the upper limit on the eta_000 parameter, |eta_000 | < 0.0088 at 90% C.L., improving by a factor two the latest direct measurement.Comment: Accepted for publication in Physics Letters B (15 pages, 13 figures

Charged kaon lifetime at KLOE

Preliminary result on the charged kaon lifetime, obtained by the KLOE experiment operating at DA$\Phi$NE, the Frascati $\phi$-factory, is presentedComment: 3 pages, 3 figures, to appear in the proceedings of 42nd Rencontres de Moriond on Electroweak Interactions and Unified Theories, La Thuile, Aosta Valley, Italy, 10-17 Mar 200

Measurements of the Absolute Branching Ratios for the Dominant KL Decays, the KL Lifetime, and Vus with the KLOE Detector

From a sample of about 10^9 Phi mesons produced at DAFNE, we have selected KL mesons tagged by observing KS->pi+pi- decays. We present results on the major KL branching ratios, including those of the semileptonic decays needed for the determination of Vus. These branching ratio measurements are fully inclusive with respect to final-state radiation. The KL lifetime has also been measured.Comment: Submitted to Phys. Lett.